Arca Biopharma | ABIO - Gross Profit On Sales


Arca Biopharma reported 0 in Gross Profit on Sales for its fiscal quarter ending in March of 2025.





Gross Profit On Sales Change Date
Amgen USD 6.89B 415M Dec/2025
Arca Biopharma 0 0 Mar/2025
Biogen USD 1.82B 169.5M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Capricor Therapeutics 11.13M 8.87M Dec/2024
Cipla INR 39.1B 2.54B Mar/2026
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 63.8M 63.56M Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Cytokinetics USD 19.2M 1.44M Mar/2026
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Grifols EUR 766.49M 39.74M Dec/2024
Laboratory Of America USD 1.01B 20.6M Mar/2026
Myriad Genetics USD 146.8M 3M Dec/2025
Otsuka Holdings JPY 456.25B 1.16B Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025